Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Apr 18;16(8):731-732.
doi: 10.1080/15384101.2017.1302232. Epub 2017 Mar 13.

Landscaping a chromatin response to MEK inhibition

Jon S Zawistowski  1 , Daniel R Goulet  1 , Gary L Johnson  1
Affiliations
Editorial

Landscaping a chromatin response to MEK inhibition

Jon S Zawistowski et al. Cell Cycle. .
No abstract available

Keywords: MEK inhibition; P-TEFb; adaptive transcriptional response; enhancer remodeling; epigenomic landscape.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Epigenomic landscape modulation as adaptation to MEK inhibition. Following trametinib treatment, triple negative breast cancer cells adapt by seeding the formation of new BRD4-rich enhancers to induce transcription of proximal receptor tyrosine kinase genes and other genes in growth/survival promotion pathways leading to drug resistance. BET bromodomain inhibition attenuates this response in combination with MEK inhibition.
See this image and copyright information in PMC

Comment on

  • Feature to: Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, et al. Enhancer Remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacological targeting of the P-TEFb complex. Cancer Discovery 2017; 7(3):302-321; PMID: ; 10.1158/2159-8290.CD-16-0653.

References

    1. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, et al.. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012; 149:307-21; PMID:22500798; http://dx.doi.org/10.1016/j.cell.2012.02.053 - DOI - PMC - PubMed
    1. Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KAL, Granger DA, Reuther RA, et al.. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep 2015; 11:390-404; PMID:25865888; http://dx.doi.org/10.1016/j.celrep.2015.03.037 - DOI - PMC - PubMed
    1. Stratikopoulos EE, Dendy M, Szabolcs M, Khaykin AJ, Lefebvre C, Zhou MM, Parsons R. Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy. Cancer Cell 2015; 27:837-51; PMID:26058079; http://dx.doi.org/10.1016/j.ccell.2015.05.006 - DOI - PMC - PubMed
    1. Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, et al.. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacological targeting of the P-TEFb complex. Cancer Discov 2017; 7(3):302–321; PMID:28108460; http://dx.doi.org/10.1158/2159-8290.CD-16-0653 - DOI - PMC - PubMed
    1. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013; 153:320-34; PMID:23582323; http://dx.doi.org/10.1016/j.cell.2013.03.036 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances